<?xml version="1.0" encoding="UTF-8"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-10-19T00:27:38Z</responseDate><request verb="GetRecord" identifier="oai:ebyu-rdlopen.rawdatalibrary.net:ebyu/12883" metadataPrefix="oai_dc">https://ebyu-rdlopen.rawdatalibrary.net/oai/request</request><GetRecord><record><header><identifier>oai:ebyu-rdlopen.rawdatalibrary.net:ebyu/12883</identifier><datestamp>2026-10-18T21:13:29Z</datestamp><setSpec>openaire</setSpec><setSpec>driver</setSpec><setSpec>com_ebyu_10000</setSpec><setSpec>col_ebyu_10001</setSpec></header><metadata><oai_dc:dc xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd"><dc:title>Can zaprinast and avanafil induce the levels of angiogenesis, bone morphogenic protein 2, 4 and 7 in kidney of ovariectomised rats?</dc:title><dc:creator>Huyut, Zübeyir</dc:creator><dc:creator>Bakan, Nuri</dc:creator><dc:creator>Yıldırım, Serkan</dc:creator><dc:creator>Akbay, Halil İbrahim</dc:creator><dc:creator>Huyut, Mehmet Tahir</dc:creator><dc:creator>Ahlatçı, Adem</dc:creator><dc:creator>Uçar, Bünyamin</dc:creator><dc:subject>Angiogenesis</dc:subject><dc:subject>avanafil</dc:subject><dc:subject>bone morphogenetic protein</dc:subject><dc:subject>phosphodiesterase-5 inhibitor</dc:subject><dc:subject>zaprinast</dc:subject><dc:subject>Animals</dc:subject><dc:subject>Female</dc:subject><dc:subject>Humans</dc:subject><dc:subject>Kidney</dc:subject><dc:subject>Ovariectomy</dc:subject><dc:subject>Purinones</dc:subject><dc:subject>Pyrimidines</dc:subject><dc:subject>Rats</dc:subject><dc:subject>Vascular Endothelial Growth Factor A</dc:subject><dc:subject>purine derivative</dc:subject><dc:subject>pyrimidine derivative</dc:subject><dc:subject>vasculotropin A</dc:subject><dc:subject>animal</dc:subject><dc:subject>human</dc:subject><dc:subject>metabolism</dc:subject><dc:subject>rat</dc:subject><dc:description>Objective: This study investigated effects of zaprinast and avanafil on angiogenesis, vascular endothelial growth factor (VEGF), bone morphogenic protein (BMP) 2, 4 and 7. Methods: Female rats were randomly divided into four groups (n = 6). Sham; abdomen was approximately 2 cm opened and closed. Ovariectomised (OVX); abdomen was opened 2 cm and the ovaries were cut. OVX + zaprinast and OVX + avanafil groups; after the same procedure with OVX, 10 mg/kg zaprinast and avanafil were orally administered for 2 month, respectively. Angiogenesis and the levels of VEGF, BMP2, 4 and 7 were determined. Results: VEGF, BMP2, 4 and 7 levels in OVX + zaprinast and especially OVX + avanafil groups were higher than the sham and OVX (p &lt;.05). However, only VEGF and BMP2 levels in OVX + zaprinast group were significant according to sham (p &lt;.05). Also, angiogenesis in OVX + zaprinast and OVX + avanafil groups was dominant according to sham and OVX (p &lt;.05). Conclusions: Zaprinast and avanafil induced BMP2, 4 and 7 levels synergistically with increased VEGF and angiogenesis in renal tissue. © 2020 Informa UK Limited, trading as Taylor &amp; Francis Group.</dc:description><dc:publisher>Taylor and Francis Ltd.</dc:publisher><dc:date>2022</dc:date><dc:type>Article</dc:type><dc:identifier>https://rdlopen.rawdatalibrary.net/r/ebyu/12883</dc:identifier><dc:identifier>https://doi.org/10.1080/13813455.2020.1740743</dc:identifier><dc:identifier>1381-3455</dc:identifier><dc:language>en</dc:language><dc:relation>Archives of Physiology and Biochemistry</dc:relation><dc:rights>info:eu-repo/semantics/openAccess</dc:rights><dc:type>info:eu-repo/semantics/article</dc:type><dc:identifier>https://ebyu-rdlopen.rawdatalibrary.net/tr/items/ebyu/12883</dc:identifier></oai_dc:dc></metadata></record></GetRecord></OAI-PMH>